tiprankstipranks
Acorda Therapeutics enters new long-term supply pact with Catalent on INBRIJA
The Fly

Acorda Therapeutics enters new long-term supply pact with Catalent on INBRIJA

Acorda Therapeutics (ACOR) announced that on December 31, 2022 it entered into a new long-term global supply agreement with Catalent (CTLT) for the manufacture of INBRIJA , or levodopa inhalation powder, at its Center of Excellence for Spray Dried Dispersions in Boston where Catalent will continue to manufacture INBRIJA through 2030. The new agreement includes the scale-up to the larger pharma grade spray-dryer at a PSD-7 scale, which will provide expanded capacity for the long-term world-wide manufacturing requirements of INBRIJA. Under the new supply agreement Acorda is required to purchase $8.5 million in INBRIJA supply in 2023 and $15.5 million in 2024, reduced from $18 million annually. Beginning in 2025, Acorda will pay a fixed capsule fee based on the amount of INBRIJA needed in the US and other markets. By 2026, an expansion in Catalent’s manufacturing capacity is expected to reduce per-capsule prices significantly. In addition, Acorda will pay an $8 million termination fee to Catalent in connection with the termination of the prior global supply agreement, payable in two installments in June and December 2023, and $1 million in each of 2023 and 2024 for capital expenditures at the manufacturing plant to assist in the capacity expansion."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ACOR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles